Observational studies have linked lower levels of omega-3 (n-3) polyunsaturated fatty acids (PUFAs) with inflammation and depression. This study was designed to determine whether n-3 supplementation would decrease serum cytokine production and depressive symptoms in 138 healthy middle-aged and older adults (average age = 51.04, SD = 7.76) who were sedentary and overweight (average BMI = 30.59, SD = 4.50). This three-arm randomized, placebo-controlled, double-blind 4-month trial compared responses to (1) 2.5 g/d n-3 PUFAs, or (2) 1.25 g/d n-3 PUFAs, or (3) placebo capsules that mirrored the proportions of fatty acids in the typical American diet. Serum interleukin-6 decreased by 10% and 12% in our low and high dose n-3 groups, respectively, compared to a 36% increase in the placebo group. Similarly, low and high dose n-3 groups showed modest 0.2% and À2.3% changes in serum tumor necrosis factor alpha, compared to a 12% increase in the control group. Depressive symptoms were quite low at baseline and did not change significantly in response to supplementation. Our data suggest that n-3 PUFAs can reduce inflammation in overweight, sedentary middle-aged and older adults, and thus could have broad health benefits. These data provide a window into the ways in which the n-3 PUFAs may impact disease initiation, progression, and resolution.
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1. Introduction 1.1. Inflammation, mental and physical health, and omega-3
Inflammation is a robust and reliable predictor of all-cause mortality in older adults (Krabbe et al., 2004) . Proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) play a role in coronary heart disease (CHD), depression, type II diabetes, arthritis, osteoporosis, Alzheimer's disease, periodontal disease, and frailty and functional decline (Ferrucci et al., 2006; Krabbe et al., 2004) . Fish, the prime source for the long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has generated considerable interest as a potential anti-inflammatory food (Lee et al., 2009; Wall et al., 2010) .
The positive effects of fish and fish oil consumption have been demonstrated across such diverse conditions as depression, CHD, rheumatoid arthritis, and macular degeneration (Goldberg and Katz, 2007; Hallahan and Garland, 2005; Hibbeln, 1998; Johnson and Schaefer, 2006; Wall et al., 2010) . Although the health benefits of fish oil may arise through a number of different mechanisms, reduced inflammation appears to be one common pathway (Shelton and Miller, 2010) .
A number of epidemiological and observational studies have demonstrated that lower n-3 PUFA levels are associated with higher serum IL-6, TNF-a, and CRP (Farzaneh-Far et al., 2009; Ferrucci et al., 2006; Kalogeropoulos et al., 2010; Kiecolt-Glaser et al., 2007) . In contrast, comparisons of supplemented and placebo groups in n-3 PUFA randomized controlled trials (RCTs), the gold standard for demonstrating causality, have not produced reliable serum cytokine differences (Calder et al., 2009; Fritsche, 2006; Kiecolt-Glaser et al., 2011; Sijben and Calder, 2007) . Problematic methodological issues
